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Immunotherapy has been studied for many years in lung cancer without significant results,
making the majority of oncologists quite skeptical about its possible application for non-small
cell lung cancer treatment. However, the recent knowledge about immune escape and
subsequent ‘cancer immunoediting’ has yielded the development of new strategies of cancer
immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including
both whole-cell and peptide vaccines have been tested both in early and advanced stages
of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4,
anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic
lung cancer. To date, these treatments have shown impressive results of efficacy and
tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials.
As these results will be confirmed, these drugs will be available in the near future, offering
new exciting therapeutic options for lung cancer treatment.
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Despite several advances in lung cancer transla-
tional research, the survival outcomes for the
majority of non-small cell lung cancer
(NSCLC) patients still remain very poor [1,2].
Recently, the introduction of targeted therapies,
including EGF receptor (EGFR) tyrosine
kinase inhibitors (erlotinib, gefitinib, afatinib)
for EGFR mutated tumors and EML4-ALK
inhibitors (crizotinib, ceritinib) for ALK-
rearranged tumors significantly improved both
median progression-free survival (PFS) and
quality of life (QoL) of metastatic NSCLC
patients [3]. However, these personalized treat-
ment options are limited to a minority of
NSCLC patients whose tumors report the tar-
get activating mutations, while platinum-based
doublet chemotherapy remains the unique
choice for the majority of them. Therefore, the
need for additional therapeutic options is
widely shared in the scientific community.
A promising field of research in oncology is
represented by immunotherapy, which has
been demonstrated to be a valid and effective
treatment option for some other malignancies
such as melanoma and prostate cancer [4,5]. The
rationale of studying immunotherapy for lung
cancer comes from the possibility of enhancing
a non-efficient or inhibited immune response
against cancer cells. A better understanding of
the expression of tumor-specific peptides and
the functional defects in immune pathways that
allow tumors to escape immune-recognition/
killing has led to the development of new
immunotherapeutic strategies with promising
activity in the clinical setting. This review pro-
vides the biological basis for immunotherapy in
NSCLC, focusing on the new emerging immu-
notherapeutic agents currently under investiga-
tion in clinical trials.
Cancer immune-features &
immunoediting
The immune response to cancer involves both
innate and adaptive compartments. Mecha-
nisms are not fully known, but they could be
explained as follows. In the complex system of
immune response to cancer, called immunoe-
diting, three phases have been identified: elim-
ination, equilibrium and escape (FIGURE 1). In
the first two phases (elimination and equilib-
rium), T-lymphocytes play the principal role
and as result of their activation, the immune
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system is able to recognize and eliminate cancer cells. In the
escape phase, malignancies become clinically relevant because
they bypass the immune system’s control by suppressing it [6].
In the first phase, the tumor’s growth induces the release of
cytokines, which activates cells of the innate compartment
(NK, gd-cells and macrophages) and makes them interact with
tumor’s surface destroying its cells [7]. Dendritic cells (DCs) are
called antigen-presenting cells (APCs) because they are able to
internalize and process tumor antigens and present them as
small fragmented peptides linked to class I and II MHC pro-
teins. Activated DCs migrate to regional lymph nodes where
they interact with naı¨ve T-cells; this results in the activation of
cancer-specific Th1 (CD4) lymphocytes, which are responsible
for strengthening the immune response by the recruitment of
CD8+ T-cells activated into cytotoxic T-lymphocytes (CTL).
Then cancer-specific Th1 CD4+ and CD8+ lymphocytes
migrate into the cancer site and kill its cells [8]. The presence
of a lymphocytic infiltrate within the tumor masses is consid-
ered in fact the direct evidence of the activity of the immune
system against malignant tumors, and in some cases, such as
ovarian cancer, this seems to have a correlation with progno-
sis [9]. In the phase called equilibrium, which can last for years,
various tumor cell clones grow and accumulate mutations, thus
exposing the immune system to different antigenic phenotypes.
These changes determine an alteration of cell death and prolif-
eration in the tumor; the disease is not yet evident in this
phase. In the last, so-called escape, stage, cancer cells gain the
ability to evade the immune system. Immunotolerance can be
induced through various mechanisms such as the activation of
a class of T-lymphocytes with immune-suppressive functions
(Treg) or tumor’s production of inhibiting cytokines such as
IL-10 and TGF-b [10]. A downregulation of NK activators such
as NKG2D, overexpression of CD46, CD55 and CD59 and a
reduced expression of class I MHC proteins are also
implicated [11–13]. An altered expression of proteins that nor-
mally regulate a Fas-induced apoptosis mediated by NKs or
CTLs (i.e., downregulation of Fas receptors and the secretion
of Fas ligand) is another possible mechanism involved in
immunotolerance to cancer [14,15].
Immunity in NSCLC
NSCLC has been considered a non-immunogenic malignancy
for years, and this opinion probably has addressed the choice
of research fields [16]. In fact, data from the analysis of NSCLC
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Figure 1. This image represents the immunoediting process that can be described by the three ‘E’: elimination, equilibrium
and escape. In the elimination phase, innate and adaptive immune systems work to eradicate the tumor cells. Tumor cells undergo
several changes and some cell variants could survive to the elimination phase and enter the equilibrium phase. Finally, tumor cells enter
into the escape phase where different mechanisms lead to tumor growth and immune evasion.
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tissues indicate that an immune reaction is present but the
local immunosuppressive compartment limits its efficacy in
controlling the tumor growth [17]. The presence of an intratu-
moral lymphocytic infiltrate has been demonstrated to have a
positive prognostic significance also in NSCLC [18,19], while a
high number of Treg cells in the tumor (e.g., squamous
NSCLC patients) seem to be correlated with a high risk of
recurrence [20]. Various antigens have been found in NSCLC
and classified into diverse classes such as cancer/testis antigens
(melanoma-associated antigen-A3 [MAGE-A3] and NY-ESO-1)
expressed by squamous NSCLC cells and silent in normal tis-
sues [21]. Moreover, gene mutations in cancer cells may produce
mutated proteins which are exclusively expressed by tumors
and function as tumor-associated antigens (TAAs). In fact,
CTLs directed against mutated antigens have been found in
NSCLC patients [22,23]. Some differences have been described
between squamous and non-squamous NSCLC in terms of
immunogenic profiles. Squamous-cell carcinoma expresses a
multitude of molecules such as p63/CK5/6/34bE-12, but does
not express TTF-1. Adenocarcinoma is instead characterized by
a wider molecular heterogeneity [24]. Differences in antigen
expression have been shown in several studies. For example,
(MAGE)-A3, MAGE-A4 and NY-ESO-1 are more frequently
expressed in squamous NSCLC than in non-squamous histol-
ogy [25,26]. These data constitute the conceptual basis to suppose
that manipulation of the immune system may be a viable treat-
ment option for NSCLC.
Immunotherapeutic strategies for cancer
In a systematic classification of the possible strategies to improve
the immune response against cancer and NSCLC, we can con-
sider two different strategies: enhancing immune-stimulating
components to start or maintain an effective response or inhibit-
ing suppressing factors that block the immune response [27]. We
can produce a positive effect on the immune system through
two main strategies. The first is the administration of immuno-
globulins directed against target-related antigens to induce pas-
sive immunization in the host. This kind of immunization is
known to confer a rapid protection and is usually administered
to immunocompromised patients. The second strategy confers
an active and durable immunization through the administration
of antigens that activate the host’s immune system. In anti-
cancer therapy, active immunization can be obtained by the cre-
ation of cancer-specific vaccines that are able to induce the acti-
vation of CD4+ and CD8+ T-lymphocytes and secretion of
specific immunoglobulins against TAAs. In fact, anti-cancer vac-
cines can be intended as a class of preparates containing TAAs
administered as peptides, recombinant proteins, gangliosides or
whole tumor cells, in combination with an adjuvant and able to
induce an active antitumor immunity in the host [28]. Another
possible way is to modulate the immune system in a non-anti-
gen-mediated way with the use of immunomodulators. For
example, the administration of immunostimulating cytokines,
such as IL-2 or IFN-a, or the use of inhibitors that block Treg
cell functions.
Vaccines for NSCLC
Whole-cell vaccines
Belagenpumatucel-L
Belagenpumatucel-L is an allogeneic whole-cell vaccine pro-
duced from four cells lines derived from three different histo-
logic types of NSCLC (one large cell carcinoma, one squamous
cell carcinoma and two adenocarcinoma) whose DNA have
been modified through the transfection of a plasmid containing
the TGF-b2 antisense transgene, which determines the downre-
gulation of TGF-b2 (FIGURE 2A). TGF-b is considered as an anti-
inflammatory cytokine that can suppress the activity of NK
cells, CTLs and APC cells, determining a blockade of the anti-
cancer activity of the immune system. TGF-b also works by
inducing FOXP3, thus converting CD4+ T-lymphocytes cells
into Treg cells with immunosuppressive activity. Moreover, a
high TGF-b2 level seems to be associated with a poorer prog-
nosis in NSCLC patients [29]. Belagenpumatucel-L has been
studied by Nemunaitis et al., in a Phase II dose variation trial
in which 75 NSCLC patients with stage II, IIIA, IIIB and IV
disease were randomized to receive 1.25, 2.5 or 5.0  107
cells/injection of the investigational drug administered in a
monthly or every other month schedule for up to a total of
16 doses [29]. A total of 81% of the patients enrolled had non-
resectable or metastatic disease and 15% of the assessable cases
showed a partial response to belagenpumatucel-L. An impor-
tant finding of the trial was the survival rate, which seems to
be dose-related; those patients who received the dosage of
‡2.5  107 cells/injection showed an improvement in overall
survival (OS) rate of 47%, while for those receiving 1.25 
107 cells/injection, the survival rate was 18%. A subgroup anal-
ysis of this study performed by Fakhrai H et al. demonstrated
a correlation between the presence of combined cellular and
humoral immune responses and an improvement in OS in
patients treated with belagenpumatucel-L. Patients with both
types of responses, defined immune-response positive (n = 11),
obtained in fact an advantage in terms of median OS com-
pared to those patients (n = 24) who were defined as immune
response-negative (32.5m 95% CI: 25.2–39.8 vs 11.6m 95%
CI: 5.6–17.6; p = 0.011). This suggested that the activity of
both immune system compartments is critical for the induction
of a clinically significant antitumor immunity by this vaccine.
Only one grade 3 toxicity has been registered, and the drug
had a good safety profile [30]. Based on these promising data,
the Phase III placebo-controlled, randomized, multinational
STOP trial has evaluated the treatment with belagenpumatucel-
L as maintenance therapy for IIIA, IIIB and IV NSCLC
patients who did not progress after frontline chemotherapy and
randomized between 4 and 17.4 weeks from the end of chemo-
therapy. A total of 532 eligible patients were enrolled (42 stage
IIIA and 490 stage IIIB/IV) and randomized to receive
18 monthly and two quarterly intradermal injections of
belagenpumatucel-L or placebo until disease progression or
withdrawal. The two arms were balanced for age, disease stage
and type; 57% of the patients had adenocarcinoma, 27% squa-
mous carcinoma and 6% large-cell carcinoma. The primary
Immunotherapy Review
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endpoint was OS. Recently, in the European Cancer Congress
2013 Presidential Session I, G. Giaccone presented the data of
this study, which did not meet its primary endpoint with a
median OS of 20.7 months for the belagenpumatucel-L arm
compared to 13.4 months in the control arm (hazard ratio [HR]:
0.75; p = 0.083). Patients treated in the belagenpumatucel-L
arm within 12 weeks of chemotherapy completion showed a
non-significant improvement in median OS compared to those
treated with placebo (20.7 vs 13.4months; HR: 0.75; p = 0.083).
A relevant and statistically significant improvement in OS was
observed in stage IIIB/IV non-adenocarcinoma patients (n = 99)
who started belagenpumatucel-L within 12 weeks of the comple-
tion of frontline chemotherapy (9.9 vs 12.3m; HR: 0.55;
p = 0.036). Moreover, radiotherapy pretreated patients, treated
with the investigational vaccine within 12 weeks of chemother-
apy completion, showed an advantage of 29.8 months in OS
(40.1 vs 10.3months; HR: 0.45; p = 0.014). Belagenpumatucel-
L showed a good safety profile in the study with only one serious
adverse event (grade 2 allergic rash). Although the study did not
meet its primary endpoint, it cannot be considered negative at
all, because the analysis carried out by the investigators identified
subgroups of patients who achieved a benefit in terms of OS [31].
These data, together with a good safety profile, support the
development and the future approval of belagenpumatucel-L
with appropriate patient selection.
GVAX
GVAX is a gene therapy vaccine that stimulates natural defenses
against tumor cells. The vaccine employs ex vivo transfection of
autologous or allogenic tumor cells with the GM-CSF gene, fol-
lowed by lethal irradiation before inoculation into the patient
(FIGURE 2B). The secretion of GM-CSF by genetically modified
tumor cells stimulates cytokine release at the vaccine site to acti-
vate APCs, which prime CD4+ and CD8+ T-cells to recognize
circulating TAAs, thereby inducing a tumor-specific cellular
immune response [32]. It has been studied for various malignan-
cies such as prostate cancer, melanoma, kidney cancer and
NSCLC. Data on the use of this vaccine in prostate cancer are
not promising and the negative results, together with a high tox-
icity, shown in two Phase III clinical trials limited further appli-
cations for this type of cancer [33,34]. Despite these non-
promising data, GVAX has also been evaluated in NSCLC
patients. A first Phase I study in which 34 patients with stage
IIB-IV NSCLC were treated with an autologous vaccine showed
disease stabilization in five patients, one mixed response and in
two patients who had undergone surgery, there was no evidence
of disease at 43 and 42 months post-operatively [35]. Subse-
quently, a second Phase I/II trial by Nemunaitis et al. has been
conducted with GVAX produced with autologous NSCLC cells.
A total of 83 patients, 20 with early-stage NSCLC and 63 with
advanced-stage NSCLC were enrolled; however, the vaccine was
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Figure 2. Whole-cell vaccines are composed of manipulated tumor cells that induce the immune system to react against
tumor. (A) Belagenpumatucel-L is produced with four cells lines representing three different histologic types of NSCLC (large cell
carcinoma, squamous cell carcinoma and adenocarcinoma) transfected with a plasmid containing TGF-b2 antisense transgene. The
downregulation of TGF-b, considered as an anti-inflammatory cytokine, determines the activation of NK cells, CTLs and APC and CD4+
T-cells (B) GVAX is a gene therapy vaccine. GM-CSF gene is transfected in tumor cells that are inoculated in the patient after lethal
irradiation. Secretion of GM-CSF by genetically modified tumor cells stimulates cytokine release at the vaccine site to activate
antigen-presenting cells, which prime CD4+ and CD8+ T-cells to recognize circulating tumor-associated antigens.
APC: Antigen-presenting cells; CTL: Cytotoxic T-lymphocytes; GM-CSF: Granulocyte-macrophage colony-stimulating factor;
NSCLC: Non-small cell lung cancer.
Review Rolfo, Sortino, Smits et al.
1176 Expert Rev. Anticancer Ther. 14(10), (2014)
Ex
pe
rt 
Re
vi
ew
 o
f A
nt
ic
an
ce
r T
he
ra
py
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
an
cy
 P
ot
ts 
on
 1
1/
10
/1
4
Fo
r p
er
so
na
l u
se
 o
nl
y.
successfully created and administered to only 43 patients
(33 with advanced stage and 10 with early stage). The most fre-
quent toxic event was skin reaction at the site of injection. Three
of the 33 patients with advanced disease had a complete and
durable tumor response and two of them maintained this
response for more than 5 years [36]. These data, although arising
from limited experiences on small number of patients, have
been considered promising. Nevertheless, the negative studies
previously conducted on prostate cancer inhibited the research
and development of other studies using GVAX.
Peptide & protein vaccines
MAGE-A3/vaccine
MAGE-A3 is a TAA that represents a promising future target for
cancer immunotherapy because it is not normally expressed in
normal human cells except in male germline cells in which this
antigen is not normally presented because of the lack of MHC
class I molecules [37]. MAGE-A3 expression has been demon-
strated in almost 35% of NSCLCs, with a trend of increase from
early (30%) to late stages (55%) [38]. Moreover, although its bio-
logical role is not clear, a greater expression of MAGE-A3 in
advanced NSCLC patients also correlates with a worse progno-
sis [39]. MAGE-A3 vaccine is composed of a recombinant protein
obtained by the fusion of MAGE-A3 antigen and part of the
protein D of Haemophilus influenzae, packaged with lipid adju-
vants (FIGURE 3A). This vaccine has been evaluated by Vansteenkiste
J. et al. in a multicenter, double-blind, randomized, placebo-
controlled Phase II trial in which 182 MAGE-A3+ patients with
stage I and II NSCLC were randomized to receive MAGE-A3
protein plus adjuvant or placebo after complete surgical resec-
tion. Patients were treated with an induction of five doses admin-
istered every 3 weeks, and then with eight doses every 3 months
as maintenance therapy. After a 28-month follow-up, for patients
in the experimental arm, there was a non-significant but clini-
cally relevant improvement in the disease-free interval, disease-
free survival and OS with HRs of 0.75 (95% CI: 0.46–1.23;
p = 0.254), 0.76 (95% CI: 0.48–1.21; p = 0.248) and
0.81 (95% CI: 0.47–1.40; p = 0.454). Treatment showed a good
tolerability profile that ensured a valid compliance of the patients
in the study [40]. Despite the small number of patients in the
study and the limited results, based on this data, a Phase III
study (MAGRIT trial) was initiated in 2007. This double-
blinded, placebo-controlled study recruited 2278 MAGE-
A3-positive stage IB, II and IIIA NSCLC patients who were ran-
domized to receive either MAGE-A3 vaccine as adjuvant therapy
or placebo after complete surgical resection [41]. The
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Figure 3. Another approach to induce immune response against cancer cells is to increase the immunogenicity of
tumor-associated antigen. (A) Protein- or peptide-based vaccine (as melanoma-associated antigen-A3, Tecemotide and CIMAVax) are
recombinant proteins obtained by the fusion of tumor associated antigens with an immunoadjuvant that is usually the immunogenic
component of a virus or a bacterium. (B) TG4010 is a viral vector vaccine composed of a modified Ankara virus that expresses
MUC-1 antigen and IL-2 gene. (C) Racotumomab is an anti-NeuGc-containing gangliosides anti-idiotype monoclonal antibody that
induces a strong specific cellular and humoral response against NeuGc. Dendritic cells are responsible for the antigen processing and the
presentation to T-cells through the interaction between MHC and TCR. In order to achieve T-cell activation, this first signal has to be
followed by a second co-stimulatory signal mediated by B7 and CD28 interaction.
TCR: T-cell receptor.
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experimental treatment was composed of 13 injections in a
27-month period after the standard of care (surgery or surgery
plus adjuvant chemotherapy). Primary endpoint of the trial was
disease-free survival and secondary endpoints were OS, lung-can-
cer-specific survival, disease-free survival at 2-, 3-, 4- and 5-year,
disease-free specific survival, anti-MAGE-A3 and anti-protein D
seropositivity rate as well as adverse events occurrence. Patient
accrual of the largest NSCLC clinical trial ever has been com-
pleted in 2011, but although expectations about its results with
their potential therapeutic implications were eagerly awaited,
through a recent press release, GlaxoSmithKline announced its
decision to stop the trial because it did not meet its first and co-
primary endpoints. Final results and publications are still
not available.
MUC1 & L-BLP25 (tecemotide)
MUC1 is a protein normally produced by many epithelial cells
and expressed on their apical surfaces and is overexpressed in an
hyperglycosilated form by various cancer cells [42]. This type of
tumor-associated MUC1 is immunologically distinct from the
one produced by normal cells and its typical hyperglycosylation
exposes the antigenic core of the protein to the action of the
immune-competent elements [43]. It seems to be involved in
tumor cell migration and resistance to chemotherapy-related
apoptosis and is partially responsible for immune system sup-
pression through CTL inhibition. Moreover, high levels of this
protein have been found to be related to a poor prognosis in can-
cer patients [44]. On the other hand, a higher level of
MUC1 natural antibodies has been found to be related to a bet-
ter prognosis in NSCLC patients [45], such as in pancreatic ade-
nocarcinoma [46] and in patients with early-stage breast
cancer [47] L-BLP25 (tecemotide) is a peptide vaccine composed
of the immunogenic portion of MUC1 protein-linked to a
lipidic adjuvant (monophosphoryl lipid A) and three lipids (cho-
lesterol, dimyristoyl phosphatidylglycerol and dipalmitoyl phos-
phatidylcholine) [48]. This vaccine targets the core of
MUC1 when hyperglycosylated and elicits an immune response
with the subsequent production of IFN-g and tumor-specific
CTL proliferation. This promising drug has been evaluated in
2007 by Butts et al. in a Phase IIB trial in which 171 stage IIIB/
IV NSCLC patients were randomized to receive best supportive
care (BSC) plus L-BLP25 (n = 88) or BSC alone (n = 83) after
response or stable disease to first-line chemotherapy [49]. Patients
in the L-BLP25 arm received a single intravenous dose of cyclo-
phosphamide 300 mg/m2 before the vaccine, followed by admin-
istration of the vaccine (1000 mcg) at 8-week intervals.
Subsequent maintenance administrations could be given at
6-week intervals until disease progression. The primary endpoint
of the study was median OS which resulted in 17.4 months for
L-BLP25 patients versus 13.0 months for the control arm
(adjusted HR: 0.739; 95% CI: 0.509–1.073; p = 0.112). Despite
the lack of statistical significance of this advantage, a subgroup
analysis of the 35 stage IIIB patients with loco-regional disease
treated with L-BLP25 plus BSC showed a 17.3-month difference
in median OS (30.6 vs 13.3 months, HR: 0.524; 95% CI:
0.261–1.052; p = 0.069) over the BSC group. The safety profile
was good with only few adverse events like mild flu-like symp-
toms and injection site reactions [50]. Although these results were
limited and non-statistically significant, the START trial, a mul-
ticenter Phase III randomized, double-blind placebo-controlled
study was initiated in 2007. In this large trial, 1239 patients with
stage IIIA/B unresectable NSCLC without progression following
chemoradiotherapy were randomized to receive weekly adminis-
trations of L-BLP25 (tecemotide) 806 mg for 8 weeks then every
6 weeks thereafter plus BSC or placebo plus BSC; both arms
continued until progression. Although there was a trend toward
improved OS (the primary endpoint of the trial) with the vac-
cine, difference from placebo did not reach statistical signifi-
cance; OS was 25.6 months in the L-BLP25 arm versus
22.3 months in the placebo group (adjusted HR: 0.88; 95% CI:
0.75–1.03; p = 0.123). The subgroup analysis of patients who
received previous concurrent chemoradiotherapy (n = 538)
showed a significant benefit of 10.2 months in OS with tecemo-
tide (HR: 0.78; p = 0.016). This advantage was absent in the
group of those who received tecemotide after sequential chemo-
radiotherapy (HR: 1.11; p = 0.38). Tecemotide has once again
been demonstrated to be a very well-tolerated treatment and a
possible valuable weapon for some patients on maintenance ther-
apy after chemoradiotherapy [51]. Based on these data, another
Phase III study of tecemotide has just been initiated – the
START-2 trial: a randomized study of patients with unresectable
stage III NSCLC who had either stable disease or objective
response following primary concurrent chemoradiotherapy
treated with L-BLP25 or placebo [52]. The INSPIRE trial is
another similar Phase III trial with tecemotide for Asian patients
with stage III unresectable NSCLC and is still recruiting
patients [53].
EGF vaccine: CIMAVax
EGFR and its ligand EGF are considered key elements in
many malignancies. Targeting EGFR pathway when mutated
with TKIs is today a very well-known treatment modality in
NSCLC [54]. Moreover, EGFR is overexpressed in a very high
proportion of NSCLCs [55]. CIMAVax vaccine is composed by
human recombinant EGF linked to a carrier protein, P64K
from Neisseria meningitides, and administered with an adju-
vant. The use of this vaccine induces the production of anti-
EGF antibodies whose activity reduces the activation of EGFR
and thereby inhibits tumor cell proliferation [56]. In a Phase II
study, 80 patients with stage IIIB or IV NSCLC previously
treated with first-line chemotherapy were enrolled. In this small
trial conducted by Neninger et al., patients were randomized to
receive either vaccination plus BSC or BSC alone. The investi-
gational vaccine was administered on days 1, 7, 14, 28 and
monthly thereafter after administration of a priming dose of
cyclophosphamide (200 mg/m2) [57]. The measurement of EGF
in patients’ serum showed reduced EGF concentrations in those
in the experimental arm, which indirectly confirmed that
CIMAVax induced production of anti-EGF antibodies. Because
of the small number of patients enrolled, the results of the
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study showed a non-statistically significant survival benefit for
patients treated with the vaccine (6.5 vs 5.3 months;
p = 0.098), but the improvement in median OS reached signif-
icance in the subgroup of patients younger than 60 years
(11.5 vs 5.3 months p = 0.0124). In addition, a statistically sig-
nificant improvement in survival (11.7 vs 3.6 months;
p = 0.002) was also seen for patients with EGF antibody
titers ‡ 1:4000. No critical side effects occurred in this trial [57].
A larger Phase II/III (Malaysian trial) study was started but
interrupted in 2011 due to poor enrollment [58].
Viral vector vaccines: TG4010
TG4010 is an anti-cancer vaccine composed by an attenuated
Ankara virus, genetically modified to express MUC1 antigen
and IL-2 [59]. The latter has been introduced to bypass the
MUC1-related T-cell suppression (FIGURE 3B) [44]. This vaccine
has been studied in a Phase II trial in which 65 patients with
stage IIIB/IV NSCLC were randomized to receive either
TG4010 in addition to cisplatin–vinorelbine chemotherapy or
the vaccine alone (continued until progression) [60]. Those
patients who progressed in the control arm were treated with a
cross-over to the experimental arm, with the same chemother-
apy regimen. The median OS was 12.7 months for the chemo-
therapy plus vaccine arm (Arm 1) and 14.9 for the vaccine
only arm (Arm 2). One-year survival rate was 53% for Arm
1 and 60% for Arm 2; in the latter, two patients experienced
stable disease for more than 6 months. A subsequent Phase IIb
trial evaluated this vaccine in a larger number of patients in
combination with cisplatin and gemcitabine. In this trial,
148 untreated patients diagnosed with stage IIIB or IV
MUC1-positive NSCLC were randomized to receive cisplatin
and gemcitabine, with or without TG4010. In the experimental
arm, the vaccine was administered with subcutaneous injections
each week for 6 weeks and then every 3 weeks until disease
progression. Primary endpoint was 6-month PFS, with a target
rate of 40% or higher in the experimental group. The results
of the trial showed that the addition of TG4010 to chemother-
apy confers a clinically relevant advantage in terms of PFS to
the patients. In fact, PFS rate at 6 months was 43% (95% CI:
33–54) in the experimental arm and 35% (95% CI: 26–45) in
the chemotherapy alone arm (p = 0.13), while no difference in
OS was demonstrated. Overall response rates (ORRs) were
43% in patients receiving the vaccine versus 27% in patients
receiving chemotherapy only. In addition, the subgroup analysis
of patients in the chemotherapy plus TG4010 group (with nor-
mal levels of activated NK cells) showed an improvement in
response rate and OS (58 vs 38%; p = 0.04 and 18 vs
11.3 months; p = 0.02, respectively) [61]. Based on these data, a
Phase IIB/III randomized, double-blind, placebo-controlled trial
started to evaluate this effect in a larger population and trying
to answer the question if the addition of TG4010 to standard
first-line chemotherapy confers an advantage to MUC1-positive
stage IV NSCLC patients. Primary endpoint is OS and the
investigators will try to prospectively validate activated NK level
as a predictive biomarker with PFS as a primary endpoint by
comparing the two treatment arms in two subgroups defined
according to the level of aNK cells at baseline (normal or
high) [62]. This trial is still active and recruiting patients [63].
Ganglioside vaccines: racotumomab
Gangliosides are part of the glycosphingolipids family present
on the cell surface membrane, enabling cell communication,
cell matrix adhesion, cell differentiation and regulation of the
immune response and are expressed on the surface of tumor
cells [64]. N-glycolylneuraminic acid (NeuGc) is a sialic acid
which has been found, conjugated with GM3 ganglioside
(NeuGcGM3) expressed by NSCLC cells and considered a
possible target for immunotherapy (FIGURE 3C) [65]. Racotumomab
(1E10) is an anti-NeuGc-containing ganglioside anti-idiotype
monoclonal antibody (mAb). Preclinical data suggest a promis-
ing activity of this vaccine [66] also in combination with chemo-
therapy [67]. In a compassionate study published in 2007 by
Alfonso et al., 34 patients with stage IIIB and 37 stage IV
NSCLC patients were treated with the anti-idiotype vaccine
after they received standard chemotherapy and radiotherapy.
Patients received 5 biweekly administration of the vaccine
followed by monthly maintenance administration. The OS was
9.93 months (95% CI: 8.61–11.25) with a 1-year survival rate
of 34%. Those patients who had ECOG performance status
1 (PS1) and started the experimental treatment after a PR or
stabilization with first-line treatments had a more consistent
benefit in OS (11.50 months; 95% CI: 7.97–15.03) and a
1-year survival of 39%. Toxicity profile was good, and the
most common side effects were local reaction at the injection
site and fever [68]. Currently, a prospective, randomized, open-
label, parallel-group, multicenter Phase III study is still recruit-
ing patients. This study will evaluate racotumomab for NSCLC
patients with advanced disease who have achieved an objective
response or stable disease with standard first-line treatment [69].
In the 2013 ASCO annual meeting, Gomez et al. presented
the data of an open, non-randomized study to evaluate if raco-
tumomab could be of benefit to patients with NSCLC in pro-
gression. A total of 180 patients were included, and after at
least 10 months of follow-up, median survival was 8.06 months
and OS rate at 24 months was 21%. A control group of
85 patients who did not receive second-line therapy or racotu-
momab showed a median survival of 6.26 months (p = 0.011)
and OS rate at 24 months was only 7%.
Immunomodulators & NSCLC
As previously explained, a possible strategy to stimulate an
immune response against cancer is to modulate the functions
of the principal actors of the immune system. Obviously, the
introduction of cancer-specific antigens leads the immune
system to react against precise targets, while immunomodula-
tion causes the enhancement of the existing mechanisms with
a wider spectrum of consequences including the aggression of
cancer cells but also autoimmunitary events. The enhance-
ment of the immune system can be obtained either with the
introduction of immune-stimulating factors such as DCs,
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injection of CTLs or activated NK cells, IL-2 or IFN-a or
by the inhibition of the immune-inhibiting elements respon-
sible for tolerance to cancer (e.g., inhibition of Treg cells and
blocking inhibiting cytokines) [27]. Historically, but not clini-
cally, relevant are the first attempts at using immunomodula-
tors for lung cancer such as the administration of BCG [70]
or mycobacterium-derived vaccine (SRL172) [71] alone or in
association with chemotherapy. Negative data emerged also
from clinical trials with PF-3512676, a synthetic TLR9-acti-
vating oligodeoxynucleotide, which works as the natural
ligand of TLR9 which enhances maturation of DCs [72,73].
Also, lactoferrin, which is an iron-binding glycoprotein found
in breast milk, has shown several immunomodulatory func-
tions [74]. Talactoferrin-a is the recombinant human variant
of lactoferrin, purified from Aspergillus niger var. awamori,
administered orally and transported to the gut-associated lym-
phoid tissue where it induces DC maturation [75]. Based on
positive data from Phase II trials [76,77], two Phase III studies
tried to evaluate the activity of talactoferrin-a in patients with
NSCLC. In the first one, the FORTIS-M trial, talactoferrin-a
was administered to patients with refractory advanced NSCLC
in comparison with placebo, and the results showed no
improvement in efficacy with this drug [78]. The second trial
(FORTIS-C trial) studied talactoferrin-a in association with
chemotherapy as a first-line treatment in advanced or meta-
static NSCLC. However, due to negative results of the
FORTIS-M trial, Agennix AG decided to stop enrollment
and analyze the results.
A promising immunotherapy approach for NSCLC is the
blockade of inhibitory ‘checkpoint pathways’, and the following
paragraphs focus on the possible therapeutic targets and on the
clinical implications of this type of approach (FIGURE 4).
CTLA-4 inhibitor: ipilimumab in lung cancer
CTLA-4 is an immunomodulatory receptor expressed by acti-
vated CD4+ and CD8+ T-lymphocytes that works as a nega-
tive regulator of T-cell-mediated immune response. Ipilimumab
is a fully human IgG1 mAb directed against CTLA-4 whose
activity prevents the interaction between CTLA-4 and its
ligands (CD80/CD86), thus producing a blockade of the
inhibitory signal provided by CTLA-4 and enhancing the acti-
vation and proliferation of tumor-specific T-cells [79,80]. Based
on the results of two randomized Phase III trial that showed an
improvement in OS for ipilimumab compared with vaccine
alone or standard dacarbazine chemotherapy, this mAb has
been approved for treatment of metastatic melanoma, repre-
senting a real turning point for patients with such an aggressive
type of cancer [81,82]. Ipilimumab has been evaluated in a
Phase II trial for advanced NSCLC and SCLC patients who
were randomized to receive as first-line therapy paclitaxel plus
carboplatin with either placebo or ipilimumab administered
concurrently (four doses of ipilimumab plus paclitaxel and car-
boplatin followed by two doses of placebo plus paclitaxel and
carboplatin) or as a phased regimen (two doses of placebo plus
paclitaxel and carboplatin followed by four doses of ipilimumab
plus paclitaxel and carboplatin). Treatment was administered
Anti-PDL1
Ipilimumab
CTLA4
CD28
TCR MHC
B7
PDL1
PD1
Anti-PD1
Tumor cell
Anergy
APC cell
T cell
Figure 4. Immune system is able to inhibit self-reaction by means of several inhibitory receptors. Some examples of these
receptors are CTLA-4 and PD-1. When CTLA-4 interacts with B7 T-cells are not appropriately stimulated and enter an anergic state.
Ipilimumab (on the right) is able to block this mechanism, thereby determining T-cell activation. PD-1 receptor elicits T-cell inactivation by
interacting with its ligand PDL-1. Tumor cells are able to overexpress PDL-1 enhancing the immune escape. Therefore, anti-PD1 and
anti-PDL1 drugs exert their action by decoying receptor and ligand, respectively.
APC: Antigen-presenting cells; TCR: T-cell receptor.
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intravenously every 3 weeks and not over 18 weeks (induction).
Patients with no progression continued ipilimumab or placebo
every 12 weeks as maintenance therapy until progression, death
or intolerance. Results for NSCLC and SCLC were published
separately. The trial met its primary endpoint, immune-related
PFS (irPFS), for NSCLC patients (n = 204) but only for those
treated with phased ipilimumab (5.7 vs 4.6 months; HR: 0.72;
p = 0.05), while in the concurrent ipilimumab group, no sig-
nificant improvement was demonstrated (5.5 vs 4.6 months;
HR: 0.81; p = 0.13). In the three groups of patients, phased,
concurrent ipilimumab and control, median OS was 12.2,
9.7 and 8.3 months, respectively. Two patients died from
treatment-related toxicity and severe adverse events seemed to
be more frequent in the concurrent group. In the phased ipili-
mumab group, patients with squamous cell carcinomas had a
more significant improvement in irPFS (HR: 0.55) than
patients with adenocarcinoma (HR: 0.82) and similar results
were found in the concurrent arm [83]. Data for patients with
advanced SCLC showed that phased ipilimumab, but not con-
current ipilimumab, improved irPFS versus control (HR: 0.64;
p = 0.03), while no improvement in PFS (HR: 0.93; p = 0.37)
or OS (HR: 0.75; p = 0.13) was obtained. In the phased, con-
current and control arms, median irPFS was 6.4, 5.7 and
5.3 months and median OS was 12.9, 9.1 and 9.9 months,
respectively. Overall rates of grade 3–4 adverse events were 17,
21 and 9% for phased ipilimumab, concurrent ipilimumab and
control, respectively [84]. These promising data led to two open
Phase III trials to evaluate ipilimumab immunotherapy for
lung cancer. The first study [85], presented at the 2013 ASCO
meeting, is a randomized, multicenter, double-blind Phase III
study comparing ipilimumab in combination with paclitaxel
and carboplatin versus placebo in addition to paclitaxel and car-
boplatin for stage IV/recurrent NSCLC patients with squamous
histology with OS as primary endpoint [86]. The second study [87],
presented at the same congress, will evaluate the efficacy of the
addition of ipilimumab to etoposide and platinum chemother-
apy for patients with extensive-stage disease SCLC in compari-
son with etoposide and platinum therapy alone [88]. These two
trials are still recruiting patients and obviously the expectations
are great about the possible clinical implications of their results.
Anti-PD-1 antibodies
Programmed cell death protein 1 (PD-1) belongs to the
B7-CD28 superfamily and works as a receptor, which can be
expressed on T-lymphocytes, B cells, NK cells, activated mono-
cytes and DCs. It normally binds two ligands: PD-L1 (B7-H1)
and PD-L2 (B7-DC) [89]. The interaction between PD-1 and its
ligands results in diminished T-cell proliferation, altered cytokine
production and initiation of T-cell exhaustion and/or apoptosis.
These functions explain the immunosuppressive role of PD-1,
which limits the risk of autoimmune reactions but also decreases
the anti-tumor activity of CD8+ lymphocytes [90]. Blockage of
this immune checkpoint is considered one of the most promising
field of study to enhance the immune response against cancer
cells, and several anti-PD-1 agents are in development: two of
them are nivolumab and lambrolizumab (MK-3475). Nivolu-
mab (BMS-936558 formerly MDX-1106/ONO-4538) is a fully
human IgG4 mAb directed against the PD-1 receptor, which
showed a promising spectrum of activity in a Phase I trial in
296 patients with refractory solid tumors including 129 patients
with NSCLC [91]. Patients were treated with five escalation doses
from 0.1 to 10.0 mg/kg every 2 weeks for up to twelve 8-week
cycles. It has been recently shown that, of the 129 pretreated
NSCLC patients (non-squamous n = 74, squamous n = 54,
unknown histology n = 1) who received nivolumab 1, 3 and
10 mg/kg IV every 2 weeks, 22 patients (17%) had responses
(CR/PR) with a median duration of 74 weeks (range 6.1+ to
133.9+ weeks). The highest ORR was at 3 mg/kg (24%) across
the various histologies. Median OS across all doses was
9.6 months and 14.9 months at 3 mg/kg across all histologies.
Median OS across all doses was similar for squamous
(9.2 months) and non-squamous patients (10.1 months), while
at the 3 mg/kg dose, a difference in median OS (9.5 months for
squamous NSCLC; 18.2 months for non-squamous) was
reported. Moreover, the 1-year survival rate was 43% for non-
squamous NSCLC patients and 39% for squamous NSCLC
patients across all doses. About the toxicity of nivolumab, any
grade adverse events was seen in 53/129 patients (41%) while
grade 3/4 events occurred only in 6/129 patients (5%) [92]. Data
of activity and tolerability of nivolumab in strongly pretreated
NSCLC patients led to the start of two Phase III trials which are
evaluating nivolumab as second-line monotherapy versus doce-
taxel both in squamous (OS and ORR as primary endpoint) [93]
and in non-squamous (OS primary endpoint) NSCLC [94].
These studies are still ongoing. Another Phase I trial is testing
nivolumab in combination with three platinum-based doublet
chemotherapy regimens (cisplatin/gemcitabine; cisplatin/
pemetrexed and carboplatin/paclitaxel), with targeted drugs
(bevacizumab and erlotinib), with ipilimumab in monotherapy
and in maintenance in patients with advanced NSCLC [95].
Nivolumab is being evaluated also as third-line therapy in a
Phase II trial with ORR as primary endpoint in patients with
advanced or metastatic squamous NSCLC after failure of two
prior systemic therapies [96]. Another Phase II trial is also evalu-
ating the epigenetic priming with azacitidine and entinostat or
oral azacitidine alone prior to nivolumab in recurrent meta-
static NSCLC patients [97]. Lambrolizumab (MK-3475) is
another anti PD-1 humanized IgG4 mAb which has been
defined by the US FDA as ‘breakthrough therapy’ for the dura-
ble results obtained in the treatment of patients with advanced
melanoma [98]. Preliminary data of MK-3475 in pretreated
NSCLC patients have been presented at the 15th World Con-
ference on Lung Cancer in Sidney, Australia. In this study,
lambrolizumab was administered at a dose of 10 mg/kg every
3 weeks in 38 treatment-refractory patients with NSCLC:
ORR was 24% and most of the responses were observed by the
time of first planned assessment at week 9 [99]. The drug is
being studied in comparison with both docetaxel in NSCLC
patients after failure of a platinum-based regimen [100] and with
chemotherapy or immunotherapy [101].
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Anti-PD-L1 antibodies
Another way to block PD1-immune checkpoint is to reduce
the activity of its ligand, and for this reason, mAbs directed
against PD-L1 are in development. PD-L1 is a transmembrane
protein expressed by various elements of the immune system
and its expression in solid tumors seems to be associated with
tumor grade, squamous histology, immune cell density and
co-localization of PD-L1+ immune cells [102]. Data from prelimi-
nary studies suggest that the expression of PD-L1 in human can-
cers evaluated with immunohistochemistry in formalin-fixed
paraffin embedded tissue samples could be a prediction test for
response to anti-PD-1/PD-L1 therapy [103,104]. In a recent study
by Velcheti et al., antibodies and in situ mRNA hybridization
were used to evaluate PD-L1 expression in NSCLC using quanti-
tative fluorescence to determine the frequency of expression and
prognostic value in two cohorts of patients from Greece
(n = 340) and USA (n = 204). PD-L1 expression was 36% in
patients from Greece and 25% in patients from the USA and it
was related to the presence of a consistent lymphocyte infiltrate
in tumors. Surprisingly, patients with protein and mRNA
PD-L1 expression showed statistically better outcome in
both groups, independent of the histology. These data are
in contrast with previous studies which reported that the expres-
sion of PD-L1 protein in various malignancies, including
in NSCLC, was associated with worse outcome [105–108].
BMS-936559 (MDX-1105) is a fully human IgG4 anti-PD-
L1 mAb that blocks the binding of PD-L1 to both PD-1 and
CD80. It has been evaluated in a Phase I trial for patients with
various types of cancers including 75 NSCLC patients. Five of
the 49 assessable NSCLC patients showed response with a
range of duration of 1.6–2.3 months. Toxicity profile was accept-
able with only 9% of grade 3/4 drug-related adverse events [104].
MPDL3280A is another anti PD-L1 mAb in development whose
modified Fc domain seems to maximize the therapeutic effects
by minimizing the antibody-dependent cellular cytotoxicity-
mediated depletion of activated T-lymphocytes. This drug has
been studied in a dose escalation Phase I trial in which
175 patients with solid tumors have been treated. Preliminary
data for the 41 evaluable NSCLC patients first dosed at 1–
20 mg/kg showed an ORR of 22% (9/41), and responses lasted
from a range of 1+ to 214+ days. Curiously, the ORR was 23%
(8/35) for former/current smokers versus 17% (1/6) for non-
smokers, and it seems also to be associated with PD-L1 tumor
status [109]. A Phase Ib trial will assess intravenous MPDL3280A
in combination with erlotinib administered to patients with
locally advanced or metastatic NSCLC [110]. MPDL3280A is
also being evaluated in three Phase II trials: in two of them as
monotherapy for patients with PD-L1-positive locally advanced
or metastatic NSCLC [111,112] and in the third one in compari-
son with docetaxel for platinum refractory patients [113]. More-
over, a Phase III multicenter, open-label, randomized,
controlled study has started to evaluate MPDL3280A in com-
parison with docetaxel in patients with locally advanced or
metastatic NSCLC after failure with platinum-containing
chemotherapy.
Expert commentary
It could be a long time before we see any hope of immunother-
apy finally turning into an option for lung cancer therapy. Lung
cancer tumors always had the reputation of not being very immu-
nogenic, and the fact that we have not really discovered the anti-
gen(s) that are key to generate an adequate immune response
have made things worse. We have tried whole-cell vaccines over
the years, we have tried several specific antigens and have done
autologous vaccinations and allogeneic ones. Finally, in the last
3 years, information from the first four randomized Phase III
clinical trials of promissory lung cancer vaccines have started
coming in; unfortunately, most of them are unable to prove
improvements in survival, but in some cases like BLP-25 (former
stimuvax) the final story is not written yet and we will have a sec-
ond chance with the new prospective randomized trial for con-
current chemoradiation patients. The new hope arrived with the
checkpoint inhibitors that are new options for immunotherapy,
and after the success of antiCTL4 in other tumors, there is a lot
of expectation to see if this agent gets approval for lung cancer.
Finally, the discovery of PD-1/PDL-1 as potential targets in lung
cancer brings another option to the table, the original data the
authors have review here is solid and very promissory.
Also, we cannot forget that, in general, immunotherapy has
proven to be less toxic than chemotherapy giving even incur-
able patients a much better QoL, so the goal is not only to try
to cure this terrible disease but also to prolong survival with
excellent and decent QoL, making lung cancer a chronic dis-
ease as first step toward the cure.
After being for many years the God that was forgotten in
the garden of the lords, the authors hope that immunotherapy
will become a major divinity.
Five-year view
Perhaps, few years ago, it was still thought that immunotherapy
would not impact lung cancer survival. Immunotherapy has had
ups and downs in lung cancer treatment roadmap. Sometimes
showing provocative and intriguing results, but without showing
an improved OS in a large Phase III randomized, placebo-
controlled trial. Nonetheless, the authors believe that soon this
paradigm will change. The advances in bio-immunology have
taught us how to target those intrinsic immune mechanisms
which are shut down by tumor cancer cells. Novel agents such
as anti-PD1 and PD-L1 antibodies are shaking all prior experi-
ences that we had had in the past trying to elicit immune
response against cancer cells using vaccines with different kind
of antigens, adjuvants (carrier) and procedures.
As we move toward the concept of ‘personalized’ or individual-
ized therapy by trying to minimize toxicity for the patient and
attain maximum response which translates into survival advantage,
perhaps the effective way to improve the immune response against
NSCLC would be by inhibiting suppressing factors that block the
immune response. These novel agents such as nivolumab, lambro-
lizumab, MPDL3280A and others are reporting good responses
in advanced NSCLC. Due to their toxicity profile, it seems that
we can combine them with chemotherapy and perhaps move
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them into early stages. This is a new field and we have to wait for
ongoing clinical trials to mature and report their results. One of
the many questions that need to be answered in the next 5 years is
which mechanism is more effective in blocking PD1 or its ligand
to exert maximum response. Also, are they effective in the adju-
vant setting? Or is this an area in which vaccination still may have
an impact? Meanwhile, the efficacy and reported data from these
immunomodulators are encouraging and giving rise to many new
hypotheses and clinical uses and clinicians should stay tuned to
developments unfolding over the next few years.
On the other hand, well-advanced clinical trials already com-
pleted or ready to start using vaccines are eagerly awaited, such
as MAGRIT and START2 trials. At the end of this journey,
the authors sense that we are finally close to the development
of an immunotherapy approach that can help us to improve
OS and cure rate in lung cancer.
Conclusions
Recently, a better understanding of the biology of immune system
in lung cancer led to the development of several immunotherapeu-
tic agents, resulting in two major proposed therapeutic strategies:
antigen-specific immunotherapy or cancer vaccination and non-
antigen-specific immunotherapy or cancer immunomodulation.
Vaccine therapy has not proven effective to date, but both activity
and very low-toxicity profile define a unique treatment opportu-
nity. Immunomodulators, working as checkpoint inhibitors in the
interaction between T-cells and cancer cells have shown impressive
activity in early clinical trials, representing the best pathway to tar-
get for the achievement of an immunological response against can-
cer cells. Waiting for the confirmatory results from ongoing
randomized Phase III trials, some issues still need to be resolved.
We need to develop more accurate predictive biomarkers for
patient selection, in order to treat subgroup of patients who could
benefit more and have their disease controlled for a long period of
time. Indeed, most of the patients who are benefiting from immu-
notherapy are disease progression free after a long time of treat-
ment, suggesting that their immune system has been reset in a
way that could allow them to live with their disease. Furthermore,
the immune response may take longer time to become clinically
evident compared with standard cytotoxic therapy, sometimes
leading to a temporary increase of the tumor target lesions because
of the inflammatory infiltrate, subsequently followed by the final
tumor shrinking. Therefore, we need to validate specific immune
response criteria for the assessment of immunotherapy activity,
because the commonly used RECIST criteria might not be appro-
priate to evaluate the activity of the new immune drugs. Even if
most of the trials so far have used immunomodulators alone in
metastatic lung cancer, we also need to work out when it is prefer-
able to use immunotherapy in the course of lung cancer, moving
our interest on early disease. Ongoing trials are exploring the use
of these agents in combination with other therapies, such as che-
motherapy, radiotherapy and targeted agents, suggesting that com-
bination treatments could increase the activity of immunotherapy
for NSCLC. Finally, combining the different immunotherapeutic
agents could also produce a synergistic effect. If these findings are
confirmed, immunotherapy will most likely become part of daily
practice for NSCLC in the near future, conferring the opportunity
to finally enter in the pantheon of lung cancer treatments.
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Key issues
• Survival outcomes of advanced non-small cell lung cancer (NSCLC) patients are still poor for the majority of them, but the introduction
of targeted therapies represented a critical turning point for the treatment of molecular selected patients.
• The immune system is widely involved in the complex mechanisms of development, growth and spreading of malignant tumors,
including NSCLC.
• Although lung cancer has been considered non-immunogenic for years, some scientific evidences suggest the opposite, especially for
squamous NSCLC.
• Two different strategies of generating an immune response against cancer: enhancing immune stimulating components to start or
maintain an effective response or inhibiting suppressing factors limiting the immune response.
• Many vaccines have been evaluated using different targets and others are still under evaluation. Promising data are coming especially
from belagenpumatucel-L, a whole-cell vaccine, melanoma-associated antigen-A3 vaccines and tecemotide, an anti-MUC1 vaccine.
• The inhibition of immune checkpoints is a possible strategy to enhance immune response against cancer.
• Ipilimumab showed promising activity in Phase II trials for patients with advanced squamous NSCLC and SCLC, improving both
progression-free survival and OS.
• Anti PD-1 antibodies, nivolumab and lambrolizumab, works through the inhibition of the interaction of PD-1 and its ligands. Preliminary
promising data encouraged the start of larger studies.
• Anti-PD-L1 antibodies BMS-936559 (MDX-1105) and MPDL3280A showed promising results, and they are currently being evaluated
both in monotherapy and in combination with other anticancer agents.
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